Xlife Sciences AG's EBIT per Share for the
six
months ended in Dec. 2025 was CHF-3.21.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-4.29.
During the past 3 years, the average EBIT per Share Growth Rate was -14.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -48.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Xlife Sciences AG's EBIT per Share or its related term are showing as below:
XSWX:XLS'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -140.1 Med: -60.45 Max: -14.1
Current: -14.1
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Xlife Sciences AG was -14.10% per year. The lowest was -140.10% per year. And the median was -60.45% per year.
XSWX:XLS's 3-Year EBIT Growth Rate is ranked worse than 82.91% of 1182
companies
in the Biotechnology industry
Industry Median: 15.45
vs XSWX:XLS: -14.10
Xlife Sciences AG (XSWX:XLS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Xlife Sciences AG EBIT per Share Related Terms
Xlife Sciences AG EBIT per Share Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-4.29
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (XSWX:XLS) has a EBIT per Share of CHF-4.29 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Xlife Sciences AG and its competitors. According to the industry distribution chart, Xlife Sciences AG ranks #980 out of 1182 companies in the Biotechnology industry, placing it in the top 82.9%.
Is Xlife Sciences AG's EBIT per Share too high?
Xlife Sciences AG's current EBIT per Share is CHF-4.29. Based on the distribution chart, Xlife Sciences AG ranks #980 out of 1182 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #980 out of 1182 companies for EBIT per Share. This places Xlife Sciences AG in the lower half of its industry. The industry median EBIT per Share is 15.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.45, based on 1,182 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Xlife Sciences AG and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current EBIT per Share is CHF-4.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.29, compared to a current price of CHF20.20 — trading 177.1% above its estimated fair value. The current EBIT per Share is CHF-4.29. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current EBIT per Share is CHF-4.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF20.20 is trading 177.1% above its estimated GF Value™ of CHF7.29.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
EBIT per Share: CHF-4.29
GF Value™: CHF7.29 vs. price of CHF20.20 (177.1% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score
Get the complete analysis for XSWX:XLS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
